June 22, 2012 Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 Clinical Trial in MDS and AML Patients DUBLIN, Calif., June 22, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasd

First Page		Document Content
Acute myeloid leukemia Myeloid leukemia Clinical research Design of experiments Myelodysplastic syndrome Astex Clinical trial Medicine Health Acute leukemia		June 22, 2012 Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 Clinical Trial in MDS and AML Patients DUBLIN, Calif., June 22, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasd Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 58,57 KB Share Document on Facebook

	Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells Lijuan Xia, Duo Chen, Rui Han, et al. Mol Cancer Ther 2005;4:Updated version DocID: 1v6bB - View Document
	The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2 DocID: 1uSbg - View Document
$A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan$	A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan DocID: 1uJQ2 - View Document
	Platelet Proteomics in Chronic Myeloid Leukemia DocID: 1uEkU - View Document
	Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1, Johanna M Erbani, PhD student2, DocID: 1u5Xi - View Document